产品
  • 产品
  • 供应商
  • 采购
  • 资讯
  • 会展
猜你想搜
首页 制药产品大全 生物制品 生化原料药 普兰林肽

普兰林肽

2026-10-31

产品详情

普兰林肽
肽类
151126-32-8
中国药典,美国药典,欧洲药典,企业标准
注射级
Pramlintide/=Symlin/=an injectable amylin analogue drug for diabetes (both type 1 and 2)
否
As per requirement
As per requirement
10克
capacity >10,000 grams
2周-4周
中国,北美洲,东欧,亚洲,中东
无

产品描述


Pramlintide (trade name Symlin) is an injectable amylin analogue drug for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca). Pramlintide is sold as an acetate salt.


Pharmacology

Pramlintide is an analogue of amylin, a small peptide hormone that is released into the bloodstream by the β cells of the pancreas along with insulin after a meal. Like insulin, amylin is completely absent in individuals with Type I diabetes.

In synergy with endogenous amylin, pramlintide aids in the regulation of blood glucose by slowing gastric emptying, promoting satiety via hypothalamic receptors (different receptors than for GLP-1), and inhibiting inappropriate secretion of glucagon, a catabolic hormone that opposes the effects of insulin and amylin. Pramlintide also has effects in raising the acute first-phase insulin response threshold following a meal.

Both a reduction in glycated hemoglobin and weight loss have been shown in insulin-treated patients with type 2 diabetes taking pramlintide as an adjunctive therapy.


Research Applications

In the research field, pramlintide has been experimented with and used as a potential treatment drug. Pramlintide has demonstrated its ability to decrease amyloid beta plaques in Alzheimer's disease mouse models.

苏州法默赛科技有限公司
访问店铺
注册资本
公司地址
联系人

公司简介

以“关爱生命、健康至上、可负担的API”为使命,我们希望与您携手合作,实现共赢,共同促进健康生活。 我司主要产品包括 司美格鲁肽、替尔泊肽、利拉鲁肽、依替巴肽、加尼瑞克、醋酸格拉替雷、特利加压素乙酸盐、奥曲肽乙酸盐、催产素乙酸盐、去氨加压素、亮丙瑞林、醋酸西曲瑞克、醋酸卡贝缩宫素、醋酸阿托西班、利那洛肽。
业务类型:
成立日期:
年营业额:
主营产品类别: